Correction: SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy [Oncotarget., 6, (2015) (12452-12467)] doi 10.18632/oncotarget.3611;SEL1L SNP rs 12435998, a predictor of glioblastoma survival and response to radio-chemotherapy

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12452-12467

  Mellai, Marta ^a   Cattaneo, Monica ^b   Storaci, Alessandra Maria ^b   Annovazzi, Laura ^a   Cassoni, Paola ^c   Melcarne, Antonio ^d   Blasio, Pasquale De ^f   Schiffer, Davide ^a   Biunno, Ida ^b,e  

^a Neuro bio oncology Center   (Italy)

^b Milan Unit   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CTO HOSPITAL   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

^f ISENET   (Italy)

Author keywords

Brain tumors; Genetic variant; Glioblastoma multiforme; Prognosis; SEL1L

Indexed keywords

DOXORUBICIN; PACLITAXEL; TEMOZOLOMIDE; VALPROIC ACID; ANTINEOPLASTIC AGENT; DACARBAZINE; PROTEIN; SEL1L PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CHILD; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SEL1L GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN TUMOR; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DACARBAZINE; DOXORUBICIN; GENOTYPE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; PACLITAXEL; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; VALPROIC ACID;

EID: 84930033325     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.26066     Document Type: Erratum

References (50)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Classification of Tumors of the Central Nervous Systems (4th edition). 2007, IARC Press: Lyon. p. 1-309.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996.
3. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-1068.
4. Scheurer ME, Etzel CJ, Liu M, Barnholtz-Sloan J, Wiklund F, Tavelin B, Wrensch MR, Melin BS, Bondy ML. GLIOGENE Consortium. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol. 2011; 172:1099-1107.
5. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006; 1:97-117.
6. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008; 1142:108-132.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.
8. Hamza MA, Gilbert M. Targeted therapy in gliomas. Curr Oncol Rep. 2014; 16:379.
9. Bralten LB, French PJ. Genetic alterations in glioma. Cancers (Basel). 2011; 3:1129-1140.
10. Van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European organisation for research and treatment of cancer phase iii trial. J Clin Oncol. 2006; 24:2715-2722.
11. Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferreo S, Barberis M, Pupa SM, Scarpa A, Ménard S. SEL1L a multifaceted protein playing a role in tumor progression. J Cell Physiol. 2006; 208:23-38.
12. Cattaneo M, Lotti LV, Martino S, Alessio M, Conti A, Bachi A, Mariani-Costantini R, Biunno I. Secretion of novel SEL1L endogenous variants is promoted by ER stress/UPR via endosomes and shed vesicles in human cancer cells. PLoS One. 2011; 6:e17206.
13. Cattaneo M, Orlandini S, Beghelli S, Moore PS, Sorio C, Bonora A, Bassi C, Talamini G, Zamboni G, Orlandi R, Ménard S, Bernardi LR, Biunno I, et al. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene. 2003; 22:6359-6368.
14. Liu Q, Chen J, Mai B, Amos C, Killary AM, eSen S, Wei C, Frazier ML. A single-nucleotide polymorphism in tumor suppressor gene SEL1L as a predictive and prognostic marker for pancreatic ductal adenocarcinoma in Caucasians. Mol Carcinog. 2012; 51:433-438.
15. Liu Q, Chen J, Wang J, Amos C, Killary AM, Sen S, Wei C, Frazier ML. Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog. 2014; 53:711-721.
16. Orlandi R, Cattaneo M, Troglio F, Campiglio M, Biunno I, Ménard S. Production of a monoclonal antibody directed against the recombinant SEL1L protein. Int J Biol Markers. 2002; 17:104-111.
17. Granelli P, Cattaneo M, Ferrero S, Bottiglieri L, Bosari S, Fichera G, Biunno I. SEL1L and squamous cell carcinoma of the esophagus. Clin Cancer Res. 2004; 10:5857-5861.
18. Ferrero S, Falleni M, Cattaneo M, Malferrari G, Canton C, Biagiotti L, Maggioni M, Nosotti M, Coggi G, Bosari S, Biunno I. SEL1L expression in non-small cell lung cancer. Hum Pathol. 2006; 37:505-512.
19. Barberis MC, Roz E, Biunno I. SEL1L expression in prostatic intraepithelial neoplasia and adenocarcinoma: an immunohistochemical study. Histopathology. 2006; 48:614-616.
20. Ashktorab H, Green W, Finzi G, Sessa F, Nouraie M, Lee EL, Morgano A, Moschetta A, Cattaneo M, Mariani-Costantini R, Brim H, Biunno I. SEL1L, an UPR response protein, a potential marker of colonic cell transformation. Dig Dis Sci. 2012; 57:905-912.
21. Cattaneo M, Baronchelli S, Schiffer D, Mellai M, Caldera V, Saccani GJ, Dalprà L, Daga A, Orlandi R, De Blasio P, Biunno I. Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. J Biol Chem. 2014; 289:2826-2838.
22. Cardano M, Diaferia GR, Cattaneo M, Dessì SS, Long Q, Conti L, De Blasio P, Cattaneo E, Biunno I. mSEL-1L (Suppressor/enhancer Lin12-like) protein levels influence murine neural stem cell self-renewal and lineage commitment. J Biol Chem. 2011; 286:18708-18719.
23. Saltini G, Dominici R, Lovati C, Cattaneo M, Michelini S, Malferrari G, Caprera A, Milansei L, Finazzi D, Bertora P, Scarpini E, Galimberti D, Venturelli E, et al. A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. Neurosci Lett. 2006; 398:53-58.
24. Saltini G, Proverbio MC, Malferrari G, Biagiotti L, Boettcher P, Dominici R, Monferini E, Lorenzini E, Cattaneo M, Antonello D, Moore PS, Zamproni I, Viscardi M, et al. Identification of a novel polymorphism in the fibronectin type II domain of the SEL1L gene and possible relation to the persistent hyperinsulinemic hypoglycemia of infancy. Mutat Res. 2004; 554:159-163.
25. Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, Schiffer D. Antigenic and genotypic similarity between primary glioblastomas and their derived neurospheres. J Oncol. 2011; 2011:314962.
26. Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics. 2009; 6:219-227.
27. Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol. 2012; 107:617-631.
28. Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011; 105:345-357.
29. Iglesias Gómez JC, Mosquera Orgueira A. An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation. Front Oncol. 2014; 4:1-12.
30. Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet. 2001; 93:207-220.
31. Schiffer D, Brain tumors. 1997, Springer-Verlag: Heidelberg. p. 1-695.
32. Apostolatos H, Apostolatos A, Vickers T, Watson JE, Song S, Vale F, Cooper DR, Sanchez-Ramos J, Patel NA. Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35. J Biol Chem. 2010; 285:25987-25995.
33. Saladi SV, de la Serna IL. ATP dependent chromatin remodeling enzymes in embryonic stem cells. Stem Cell Rev. 2010; 6:62-73.
34. Gutmann DH. The taxonomy of brain cancer stem cells: what's in a name?. Oncoscience. 2014; 1:241-247.
35. Luco RF, Misteli T. More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr Opin Genet Dev. 2011; 21:366-372.
36. Ballaré C, Zaurin R, Vicent GP, Beato M. More help than hindrance: nucleosomes aid transcriptional regulation. Nucleus. 2013; 4:189-194.
37. Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, Jeong CH, Hou Y, Jeun SS. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol. 2012; 2012:987495.
38. Alvarez AA, Field M, Bushnev S, Longo MS, Sugaya K. The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells. J Mol Neurosci. 2015; 55:7-20.
39. Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med. (Berl). 2011; 89:303-315.
40. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011; 77:1156-1164.
41. Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB. Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol. 2011; 28:556-570.
42. Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F, Regli L, Robe P. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs. 2012; 21:1391-1415.
43. Dichamp C, Taillibert S, Aguirre-Cruz L, Lejeune J, Marie Y, Kujas M, Delattre JY, Hoang-Xuan K, Sanson M. Loss of 14q chromosome in oligodendroglial and astrocytic tumors. J Neurooncol. 2004; 67:281-285.
44. Galli R. The neurosphere assay applied to neural stem cells and cancer stem cells. Methods Mol Biol. 2013; 986:267-277.
45. Sun Y, Pollard S, Conti L, Toselli M, Biella G, Parkin G, Willatt L, Falk A, Cattaneo E, Smith A. Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci. 2008; 38:245-258.
46. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4:568-580.
47. Malferrari G, Monferini E, De Blasio P, Diaferia G, Saltini G, Del Vecchio E, Rossi-Bernardi L, Biunno I. High-quality genomic DNA from human whole blood and mononuclear cells. Biotechniques. 2002; 33:1228-1230.
48. Cattaneo M, Zollo M, Malferrari G, Orlandi R, D'Angelo A, Ménard S, Biunno I. Allelic polymorphisms in the transcriptional regulatory region of human SEL1L. Mutat Res. 2001; 458:71-76.
49. Kyöstilä K, Cizinauskas S, Seppälä EH, Suhonen E, Jeserevics J, Sukura A, Syrjä P, Lohi H. A SEL1L mutation links a canine progressive early-onset cerebellar ataxia to the endoplasmic reticulum-associated protein degradation (ERAD) machinery. PLoS Genet. 2012; 8:e1002759.
50. Cattaneo M, Canton C, Albertini A, Biunno I. Identification of a region within SEL1L protein required for tumour growth inhibition. Gene. 2004; 326:149-156.